42 results on '"Manegold, C"'
Search Results
2. Bone matters in lung cancer
3. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study
4. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer
5. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer
7. Das trimodale Therapiekonzept des malignen Pleuramesothelioms: Pleurektomie/Dekortikation, 4 Zyklen Chemotherapie mit Cisplatin/Permetrexed und Bestrahlung: FV201
8. Cetuximab treatment in combination with gemcitabine/docetaxel or carboplatin/gemcitabine for chemonaïve patients with advanced non-small cell lung cancer (NSCLC): Report on toxicity data from the ongoing Phase II/III GemTax IV study: PP403
9. Aromatic L-amino acid decarboxylase deficiency: Clinical features, drug therapy and follow-up
10. Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
11. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
12. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
13. Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant pleural mesothelioma
14. A Phase II/III Randomized Study in Advanced Non-Small Cell Lung Cancer (NSCLC) with First Line Combination versus Sequential Gemcitabine and Docetaxel: Second Interim Study Results
15. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
16. Determinants of long-term highly active antiretroviral treatment efficacy
17. Assessment of the Hypermethylation Status in Genomic DNA Samples Derived from Serum of Patients with Lung Cancer
18. Gefitinib (Iressa® ZD1839): Single-Institution Experience with an Oral Dose of 250 mg/day from an Expanded Access Program (EAP) Involving Patients with Advanced Small-Cell Lung Cancer (NSCLC)
19. Docetaxel (Taxotere®) in der First-line-Therapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms (NSCLC)
20. Hypermethylation pattern in serum-derived genomic DNA from patients with lung cancer: P762
21. Final data from a pilot trial of gefitinib (‘Iressa’, ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer: Safety and pharmacokinetics: P755
22. Single-agent gemcitabine and docetaxel given sequentially every 3 weeks in advanced NSCLC: Final results of a randomized phase-II-study show effective treatment: P753
23. Pemetrexed versus docetaxel: A phase III-study in patients with advanced non-small cell lung cancer who were previously treated with chemotherapy: V307
24. A single center, controlled study of standard versus dose intensified chemotherapy with sequential reinfusion of hematopoetic progenitor cells in small cell lung cancer, final results: V305
25. Phase-II randomized study of pemetrexed + carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: 2513
26. ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study
27. Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)
28. Molecular and immunological screening of peripheral blood samples from patients with lung cancer: 92
29. Final results from a randomized phase II study with single agent gemcitabine (G) and docetaxel (D) given sequentially every 3 weeks in advanced NSCLC
30. A phase III clinical trial of ZD1839 (‘Iressa’) in combination with gemcitabine and cisplatin in chemotherapynaive patients with advanced non-small-cell lung cancer (INTACT 1)
31. STANDARD (SCT) VERSUS DOSEINTENSIFIED CHEMOTHERAPY (ICT) WITH SEQUENTIAL RE-INFUSION OF PERIPHERAL BLOOD CELLS (PBC) IN SCLC
32. ENDOBRONCHIAL ULTRASOUND (EBUS) FOR DETECTION OF EARLY LUNG CANCER
33. Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: A multi-centre phase II study
34. Endobronchial Ultrasound (EBUS) - Assessment of a New Diagnostic Tool in Bronchoscopy for Staging of Lung Cancer
35. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™) and cisplatin: A multicenter phase II trial
36. Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy
37. Topotecan in the Therapy of Brain Metastases in Lung Cancer
38. Topotecan (Hycamtin®) in the Therapy of Small-Cell Lung Cancer
39. Concurrent Radiochemotherapy with Ifosfamide in Locally Advanced Unresectable Non-Small-Cell Lung Cancer
40. Concurrent Radiochemotherapy with Ifosfamide in Unresectable Stage III Non-Small-Cell Lung Cancer
41. Liposomal Doxorubicin as a Long-Term Treatment for Advanced HI V-Associated Kaposiʼs Sarcoma: 30 Months of Treatment
42. HIV-related Non Hodgkinʼs Lymphoma of the Gastrointestinal Tract
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.